November 18, 2026
Health news, explained with evidence
LIVE

Researchers Reveal New Mechanism of HIV Drug Lenacapavir

🧠 AI Analysis 1 min read 👁 6

A multi-institutional study reveals that the long-acting HIV medication lenacapavir disrupts the late stages of viral assembly, creating unusually large and noninfectious particles.

Researchers Reveal New Mechanism of HIV Drug Lenacapavir🧠AI Analysis

Photo: Medical Xpress

Key points

  • Lenacapavir binds to both mature capsid and precursor Gag proteins.
  • The interaction creates abnormally large, noninfectious viral particles.
  • Findings reveal dual-stage antiviral activity during the HIV life cycle.

A collaborative team of researchers from institutions including Kumamoto University and Hamamatsu University School of Medicine has uncovered an additional mechanism by which the HIV prevention and treatment drug lenacapavir operates. Published in the Proceedings of the National Academy of Sciences, the study details how the medication interferes with the late life cycle of the human immunodeficiency virus.

Led by Kazuaki Monde and Yasumasa Iwatani, the investigators discovered that lenacapavir binds to both the mature capsid protein and its precursor, known as the Gag protein. This unexpected interaction prevents normal particle assembly, resulting in virus-like structures measuring over 200 nanometers across, compared to the standard size of 100 to 130 nanometers. While these oversized particles can still fuse with target cells, they fail to establish a productive infection.

What to know: The findings suggest that lenacapavir works across multiple stages of viral replication rather than just blocking initial entry or early steps. Readers should consult a qualified healthcare provider for personal medical decisions and advice regarding HIV treatment or prevention options.

Source Medical Xpress — medicalxpress.com/news/2026-11-hiv-drug-lenacapavir-disrupt-virus.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.